ESMO17

News

ESMO 2017 round up: BMS and AZ bounce back

Europe’s biggest cancer congress ESMO wraps up today, having delivering its fair share of major studies and talking points in cancer treatment over five days.

News

Opdivo and Tafinlar+Mekinst hailed in earlier melanoma treat...

Two new regimens look set to transform treatment to delay melanoma returning in patients after surgery.

News

Colon cancer treatment can be shortened to spare patients to...

While much of the research at ESMO is based on breaking new ground and upping the ante against cancer, some studies focus on fine-tuning existing treatment to improve patient quality of lif

News

Cyramza could help bladder cancer patients who don't respond...

The field of bladder cancer treatment is developing at lightning speed, but the future doesn't necessarily belong exclusively to immunotherapy.

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Tagrisso on target to be EGFR+ lung cancer standard

New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer.

News